Find Academic Supervisors

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +3 more

Sudip Bhandari is a Researcher affiliated with the Faculty of Science and Engineering at Macquarie University , with a focus on proteomics and environmental toxicology. His research investigates molecular responses to anthropogenic stressors in ecological systems. Primary Email: sudip.bhandari@hdr.mq.edu.au Research Interests: Environmental Toxicology Proteomics Ecotoxicology Biomarker Discovery Mass Spectrometry Alpine Ecology Recent Research Activity (2025): Sudip has co-authored two publications analyzing proteomic responses to environmental stressors: one examining lead toxicity in House Sparrows from mining towns, and another studying anthropogenic impacts on Australian Alpine plants. These works highlight his specialization in environmental proteomics and ecotoxicological biomarkers.

• Proteomics
• Environmental Toxicology
• Ecology
• +3 more

Dr. Rebecca San Gil is a Lecturer at the School of Medical Sciences , University of Sydney, Australia. She leads the NeuroMolecular Discovery Group within the Neuroscience theme and is a member of the Charles Perkins Centre . Her research focuses on the molecular mechanisms underlying neurodegenerative diseases such as motor neuron disease (MND) and frontotemporal dementia (FTD) , with an emphasis on protein aggregation, stress responses, and therapeutic discovery. PhD, University of Wollongong (2018) Postdoctoral Research, Queensland Brain Institute (2018–2025) Endeavour Research Fellow (University College London) Her research spans molecular biology , neurosciences , and biochemistry , integrating techniques like genome-wide CRISPR screening , multi-omics analysis , and translational research . Key themes include the role of molecular chaperones , heat shock response , and protein folding dynamics in mitigating neurodegeneration. Dr. San Gil’s recent publications (2016–2025) highlight her work on TDP-43 pathology , heat shock proteins , and therapeutic strategies across ALS/FTD models. She has received awards such as the FightMND Early Career Research Fellow and the Sydney Dementia Network Future Research Leader Award (Travel Support Scheme) in 2025. Scientific Awards : FightMND Early Career Research Fellow, Sydney Dementia Network Future Research Leader Award (2025) Dr. San Gil actively mentors researchers like Celine CHYE and collaborates with institutions globally. Her team welcomes new members to explore neurodegenerative disease biology and therapeutic discovery .

• Neurodegenerative Diseases
• Motor Neuron Disease (MND)
• Frontotemporal Dementia (FTD)
• +7 more

Sultan Mia is an Adjunct Senior Lecturer at the Institute of Agriculture, The University of Western Australia. His research focuses on plant genetics and crop science, particularly in the area of drought tolerance in wheat and other crops. He is actively involved in genomic and proteomic studies to identify biomarkers and candidate genes associated with stress tolerance. Dr. Mia's research spans several key areas in agricultural science, including drought tolerance, plant breeding, and genomics. His work utilizes advanced techniques such as genome-wide association studies (GWAS), proteomic analysis, and genotyping to understand the molecular basis of stress responses in crops. Specific interests include the development of drought-tolerant wheat varieties through the identification of quantitative trait loci (QTL) and candidate genes. Recent publications by Dr. Mia demonstrate a strong focus on drought tolerance mechanisms in wheat and other crops. His work integrates genomics, proteomics, and metabolomics to identify key biomarkers and genetic markers. Notable contributions include the discovery of SNP markers for drought tolerance in wheat and the investigation of antioxidant responses in buckwheat under drought stress. These studies highlight a trend towards multi-omics approaches for crop improvement. Dr. Mia has supervised at least one doctoral thesis, as indicated by the "Supervised Work (1)" in his profile. While specific grant details are not provided, his research output suggests involvement in collaborative projects addressing agricultural challenges, particularly in the context of climate change and water scarcity.

• Drought Tolerance
• Plant Breeding
• Genomics
• +3 more

Anne Holland is Professor of Physiotherapy and Head of Respiratory Research at Monash University and Alfred Health in Melbourne, Australia. She is an NHMRC Leadership Fellow (2021–2025) and a Chief Investigator for the NHMRC Centre of Research Excellence in Pulmonary Fibrosis and the NHMRC Centre of Research Excellence in Treatable Traits. Her research focuses on supportive therapies for chronic respiratory diseases, particularly COPD and pulmonary fibrosis, with a strong emphasis on pulmonary rehabilitation, telerehabilitation, and ambulatory oxygen therapy. Her research interests include: Respiratory physiotherapy Pulmonary rehabilitation (home-based and low-cost models) Access to care for chronic lung disease Telerehabilitation and digital health Symptom management in interstitial lung disease Exercise training and physical activity promotion Her recent publications focus on symptom management, digital self-management tools, treatable traits models, and clinical trials in pulmonary fibrosis and COPD. The body of work reflects a strong trend toward patient-centered, accessible, and evidence-based interventions that improve quality of life and clinical outcomes in chronic respiratory conditions. Her major scientific awards include: Society Medal, Thoracic Society of Australia and New Zealand (2021) European Respiratory Society Gold Medal for Allied Health Professionals (2022) NHMRC Investigator Fellow (Leadership 1) (2021) Fellow, Thoracic Society of Australia and New Zealand (2019) American Thoracic Society Pulmonary Rehabilitation Assembly Award (2016) Anne Holland supervises PhD students and is actively involved in advising and grant leadership. She is the Primary Chief Investigator on major trials such as the PERFORM trial and the TAPPET trial, and she leads a multinational ambulatory oxygen trial for fibrotic lung disease. Her work is supported by NHMRC and international collaborations. She is also President of the Thoracic Society of Australia and New Zealand, reflecting her leadership in the field. Anne leads the Holland Respiratory Care Research Group at Monash, which focuses on innovative models of care delivery, validation of remote monitoring tools, and improving patient self-management in chronic lung disease. The team collaborates widely across Australia and internationally, particularly in trials involving pulmonary rehabilitation and treatable traits.

• Respiratory Physiotherapy
• Pulmonary Rehabilitation
• COPD
• +7 more

Dr. Ling Zhu is an Associate Professor and Senior Research Fellow at the Save Sight Institute, University of Sydney. He holds dual affiliations with the Centre for Drug Discovery Innovation and the University of Sydney Nano Institute. His research focuses on retinal diseases, including diabetic retinopathy, age-related macular degeneration, and macular telangiectasia type 2, combining clinical and basic research approaches. Dr. Zhu leads a lab with a postdoc, two research assistants, and one HDR student, emphasizing innovative techniques like human retinal explant culture and nanomedicine. Dr. Zhu obtained his PhD in Biochemistry from Rutgers University (USA) in 2008. His work has attracted over $2 million in research funding in the past five years and includes 93 publications (3590 citations, H-index 34). He is a major author in leading journals like eLife and Ophthalmology . Current research projects include preclinical RNA-LNP therapy for retinal degeneration, targeting retinal metabolism for macular diseases, and developing a 'Macula-on-a-Chip' drug screening platform. His expertise spans biochemistry, molecular biology, and translational nanomedicine. Key achievements include establishing human retinal explant models and advancing lipid nanoparticle-based drug delivery systems. Dr. Zhu collaborates widely, with projects addressing unmet clinical needs in ophthalmology and drug discovery.

• Ophthalmology
• Retinal Degeneration
• Nanomedicine
• +3 more

Associate Professor Susanna Park is an academic in Neuroscience at the School of Medical Sciences, University of Sydney. She leads a research group investigating neuropathy and neuromuscular diseases, with a focus on chemotherapy-induced peripheral neurotoxicity. Her work emphasizes clinical assessment tools and axonal degeneration mechanisms. Park holds affiliations with the Brain and Mind Centre and the Faculty of Medicine and Health. Education: PhD from University of New South Wales (UNSW) Notable Fellowships: RG Menzies/NHMRC Overseas Biomedical Fellowship (2011–2014) Research Interests: Clinical neurophysiology, blood-based biomarkers, and motor neuron disorders. Her studies address nerve excitability, chemotherapy-induced neuropathy, and inflammatory neuropathies. Park’s translational work includes developing clinical tools for neuropathy assessment in cancer patients. Publications focus on chemotherapy-induced neuropathy mechanisms, axonal degeneration, and biomarker discovery. Recent work explores electroacupuncture for neuropathy management and plasma lipidomics in risk assessment. Awards: 2022 SUPRA Supervisor of the Year finalist, 2018 RD Wright Fellowship Labs/Teams: Brain and Mind Centre, collaborating with international consortia like the Toxic Neuropathy Consortium.

• Clinical neurophysiology
• Chemotherapy-induced peripheral neuropathy
• Axonal degeneration
• +8 more

Professor Daniel Catchpoole serves as Deputy Head of School (Research) at the School of Computer Science, University of Technology Sydney (UTS), holding dual appointments at UTS and The Children's Hospital at Westmead. With over 20 years of research experience, he bridges computational sciences and pediatric cancer research through the Biomedical Data Science Lab in the Australian Artificial Intelligence Institute. His work integrates data analytics, artificial intelligence, and software development with molecular cancer biology to transform pediatric cancer treatment pathways. PhD in Cancer Cell Biology, University of New South Wales (1991-1995) Founding Fellow, Royal College of Pathologists Australasia (2010-present) Head, Children's Hospital at Westmead Tumour Bank (2001-present) Professor Catchpoole's research focuses on translational applications of genomics in childhood cancers, particularly acute lymphoblastic leukemia and neuroblastoma. His work combines high-throughput genomic technologies with advanced computational analysis to develop systems biology approaches for cancer patient assessment. Recent projects explore virtual reality applications for complex genomic data visualization and copper chelation therapies to enhance neuroblastoma immunotherapy. His research has received significant funding from Cancer Institute NSW, Sony Foundation, ARC, and NHMRC. His publication record spans biomedical data science, cancer genomics, and virtual reality applications in oncology. Recent work demonstrates leadership in 3D latent diffusion models for tumor segmentation, biobank economics, and innovative immunotherapies. His research consistently addresses the critical need for actionable knowledge from complex multidimensional biomedical data. Editorial Board Member, Cancers (2023) Associate Editor, Innovations in Digital Health, Diagnostics and Biomarkers (2019) Founding member and first President, Australasian Biospecimens Network Association Professor Catchpoole has supervised 17 Honours students (including 6 First Class Honours), 3 MSc students, and 12 PhD candidates across multiple institutions, with 6 current PhD students. His collaborative research bridges UTS's Faculty of Engineering and IT with The Children's Cancer Research Unit at The Children's Hospital at Westmead. Significant research funding includes Cancer Institute NSW grants, Sony Foundation VR projects, and ARC Discovery Projects focused on genomic data analysis and clinical decision support systems. His leadership extends to building frameworks for translational research, managing biobanks and clinical data linkages, and navigating governance requirements for cancer research. The Tumour Bank at Kids Research, CCRU, represents his long-standing commitment to pediatric cancer infrastructure development.

• Childhood Cancer Research
• Genomics
• Biomedical Data Science
• +6 more

Carlos Salomon Gallo is a Professor and NHMRC Investigator Fellow (EL2) at The University of Queensland's Centre for Clinical Research, affiliated with the School of Biomedical Sciences. He directs the Centre for Extracellular Vesicle Nanomedicine and leads the Exosome Biology Laboratory. A globally recognized key opinion leader in extracellular vesicles (ranked 3rd worldwide by Expertscape), his research focuses on EV biology for diagnostic and therapeutic applications in ovarian cancer, gestational diabetes, preeclampsia, and other obstetrical syndromes. His research integrates proteomics (SWATH-MS), miRNA analysis, and advanced isolation techniques to develop liquid biopsies. Core interests include: EV biomarker discovery and validation for early disease detection. Mechanisms of EV-mediated signaling in metabolic and oncological pathologies. Engineering EVs for targeted drug delivery and CRISPR-Cas therapeutics. Clinical translation of EV-based diagnostics (IVDs) and therapeutics. Analysis of his recent articles reveals a dominant focus on EV profiling in pregnancy complications (gestational diabetes, preeclampsia) and oncology (ovarian cancer), utilizing multi-omics approaches. Key trends include developing high-sensitivity EV biosensors, understanding hypoxia-induced EV signaling, and exploring 3D models for EV research. He has received significant recognition, including: NHMRC Emerging Leadership Fellow NHMRC Investigator Fellow (EL2) He leads the Exosome Biology Laboratory and the UQ Centre for Extracellular Vesicle Nanomedicine, fostering cross-disciplinary collaboration. His work involves extensive national and international partnerships, evidenced by leadership roles in the Centre for Clinical Diagnostics and over 20 invited international talks in 5 years. He actively mentors HDR students and contributes to global EV research standards (MISEV2023).

• Extracellular Vesicles
• Biomarker Discovery
• Exosome Biology
• +7 more

Fabio Zanini is an Associate Professor at the University of New South Wales (UNSW) , leading a research group focused on computational biology , single-cell approaches , and transcriptomic analysis across diseases like severe dengue , neonatal lung disease , cancer , and marine biology . He previously conducted postdoctoral research at Stanford University (2016-2019) and earned a PhD in Bioinformatics from the Max Planck Institute for Developmental Biology and the University of Tuebingen (2015). Current Affiliation: Group leader, UNSW Previous Training: Postdoc (Stanford), PhD (Max Planck/University of Tuebingen) His research spans single-cell RNA sequencing , computational virology , developmental cell biology , and bioinformatics tool development , with recent work on: Severe dengue progression (viral-host interactions, immune signatures) Lung development (endothelial cell diversity, hyperoxia-induced injury) Cancer genomics (mutant HSC clones, AZA therapy response) Marine biology (plankton transcriptomics, evolutionary analysis) Bioinformatics (HTSeq 2.0, northstar algorithm) Recent scientific awards include grants from the Chan Zuckerberg Initiative ($270,000), NIH R01 (multiple), ARC Discovery Grant , and NHMRC Ideas Grant . Notable contributions include: Northstar - Cell classification algorithm SpectralSeq - Hyperspectral-transcriptomic integration Tabula Muris - Mouse aging atlas He has supervised research into hematopoietic stem cell regulation , lung vascular development , and autophagy in viral infections , with collaborations across Stanford , University of Sydney , and Harvard .

• Computational Biology
• Single-Cell RNA Sequencing
• Virology
• +4 more

Professor Donald Wlodkowic is a faculty member at RMIT University's School of Science (Biosciences), leading the Neurotox Laboratory. His research focuses on aquatic ecotoxicology, behavioral ecotoxicology, and eco-neurotoxicology, with expertise in neurotoxins, industrial pollutants, and neuroactive drugs' effects on central nervous systems. He innovates biomicrofluidic technologies and digital video-based analysis for high-throughput behavioral studies in toxicology. Research Interests: Aquatic toxicology, neurotoxicology, water quality, and eco-neurotoxicology. His lab develops real-time biomonitoring systems and early-warning tools for water quality assessment. Current projects include neurotoxicity studies of pollutants, high-throughput behavioral assays, and embryo-based risk assessment. Teaching: Coordinates courses in cell biology, biochemistry (BIOL2146/2333/2420, PROC2048) and supervises honors projects (ONPS2313). He integrates digital tools into bioscience curricula for innovative teaching. Advising & Leadership: Supervises Masters and PhD students in projects such as 'Emerging Pollutants on Aquatic Animal Behavior' and 'Nanotoxicology.' He has led international academic-industry collaborations in Australia, New Zealand, and Europe, fostering motivated research teams. Labs & Teams: NeuroTox Lab pioneers interdisciplinary research in ecotoxicology and neurotoxicology, combining microfluidics, digital analytics, and behavioral assays to address environmental and health challenges.

• Aquatic Ecotoxicology
• Behavioral Ecotoxicology
• Eco-Neurotoxicology
• +7 more

Dr. Zhi-Ping Feng is a Bioinformatician at the John Curtin School of Medical Research (JCSMR), Australian National University (ANU). Her research focuses on integrating omics data with protein structure-function relationships to study interactions between macromolecules. She has expertise in analyzing genomic and transcriptomic data (e.g., RNA-Seq, ChIP-Seq) and protein structure determination via nuclear magnetic resonance (NMR) spectroscopy. Previously, she held a Senior Research Fellow position at the Walter and Eliza Hall Institute (WEHI) from 2009, working on quality control in omics research and genomic data analysis. Her postdoctoral work at WEHI (2002–2005) involved structural biology of malaria-related proteins, supported by an Australian Postdoctoral Fellowship. She holds a PhD in protein bioinformatics from China and a physics background from Peking University. Education: PhD in Protein Bioinformatics (China) Bachelor’s in Physics, Peking University Research Interests: Her work bridges computational biology and structural biology, with emphasis on: Intrinsically unstructured proteins (IUPs) and their applications in malaria proteomics Omics data integration for disease modeling (e.g., cancer, diabetes, neurodegeneration) Protein-protein interaction networks and structural bioinformatics Publications: Recent work spans cancer immunotherapy, miRNA regulation in retinal degeneration, and T cell biology, with contributions to understanding Wnt signaling in joint replacement complications and genetic fusions in pediatric brain tumors. Awards: Australian Postdoctoral Fellowship (2005) Grants/Teams: Currently affiliated with ANU Bioinformatics Consultancy, supporting translational medical research in immunology, cancer, and genomics. Labs/Teams: Collaborates with the JCSMR’s multidisciplinary teams focusing on biomedical informatics and translational research.

• Bioinformatics
• Genomics
• Proteomics
• +3 more

Senani N.H. Rathnayake is a Research Fellow at the University of Technology Sydney (UTS), Faculty of Science. He completed his PhD at UTS (2019-2024) and held a Postdoctoral Fellowship at the University of Groningen (2023-2024). His primary research focuses on respiratory diseases, particularly the molecular mechanisms of smoking-induced lung damage, COPD, and asthma. Key areas include gene expression profiling, epigenetic changes, and cellular responses to cigarette smoke exposure. Research Interests: Transcriptomic and epigenetic alterations in lung diseases Smoking cessation effects on airway biology Genetic regulation of COPD biomarkers (e.g., sRAGE) Sex chromosome influences on respiratory disease susceptibility Awards & Fellowships: 2023 TSANZ Past Presidents Scholarship Award 2022-2023 European Respiratory Society Short-Term Fellowship Recent Research Trends: His articles emphasize smoking's impact on bronchial epithelial cells, including transcriptomic shifts, mucus barrier dynamics, and CRISPR-based gene-editing applications. Recent work explores Y-chromosome effects on COPD and asthma pathogenesis. Professional Engagement: Co-chair of the 2023 TSANZ Annual Scientific Conference Member of Australian Society for Medical Research, European Respiratory Society, and Thoracic Society of Australia and New Zealand

• Respiratory diseases
• Epigenetics
• Molecular Biology
• +5 more

Andrew Currie is a Professor and Associate Dean (Research & Innovation) at Murdoch University's School of Medical, Molecular and Forensic Sciences, within the College of Environmental and Life Sciences. He leads the Sepsis Diagnostics Research Group at the Centre for Molecular Medicine and Innovative Therapeutics and co-heads the Neonatal Infection and Immunity Team with Clinical Professor Tobias Strunk at the Wesfarmers Centre of Vaccine & Infectious Diseases at Telethon Kids Institute. His research focuses on immunology and infectious diseases in pediatric populations, particularly sepsis diagnostics and neonatal immunity. Education: PhD (Immunology, University of Western Australia, 2001); BSc (Biotechnology with Honors, Murdoch University, 1997). Research Interests: Sepsis diagnostics, innate immunity mechanisms in neonates, medical biotechnology for diagnostics (e.g., biosensors), and translational research in pediatric infections. Collaborates internationally with institutions in Canada, Denmark, the UK, US, and China. Aims to reduce sepsis burden in vulnerable populations through advanced molecular methods and interdisciplinary partnerships. Key Affiliations: Lead of Sepsis Diagnostics Research Group (Murdoch University), Senior Lecturer in Immunology, Honorary Associate at Kids Research Institute Australia. Past roles include leadership in the Centre for Molecular Medicine and Innovative Therapeutics. Scientific Contributions: Over 100 peer-reviewed articles focusing on sepsis biomarkers, neonatal immunity, tick-borne diseases, and clinical trials for interventions like vitamin C and probiotics in critical illness. Active in developing precision medicine approaches for neonatal sepsis. Grants & Funding: Co-leads major projects on sepsis diagnostics and neonatal infection, supported by national and international grants. Collaborates on multi-institutional initiatives. Labs/Teams: Sepsis Diagnostics Research Group (Murdoch) and Neonatal Infection and Immunity Team (Telethon Kids Institute). Works closely with the Personalised Medicine Centre and Health Futures Institute.

• Sepsis
• Innate Immunity
• Neonatal Immunology
• +5 more

Dr. Nicole Mifsud is a Senior Research Fellow and Group Leader of the Clinical Immunology Laboratory at Monash University's Department of Biochemistry & Molecular Biology and the Monash Biomedicine Discovery Institute. She holds a PhD in Immunology (University of Melbourne, 2005), specializing in transplantation immunology. Her research focuses on T cell-mediated immune responses, particularly T cell cross-reactivity in human disorders like autoimmunity, drug allergy, and transplant rejection. She explores mechanisms underlying TCR/peptide/HLA interactions and their role in translational medicine and immunotherapeutics. Education: PhD in Immunology, University of Melbourne (2005) Honours (H1), Immunology, University of Melbourne (2000) Bachelor of Biological Sciences, La Trobe University (1992) Research interests include transplantation immunology, viral immunity, and T cell cross-reactivity. Her work contributes to UN Sustainable Development Goals related to health and well-being. Notable collaborations span institutions like the Ludwig Institute for Cancer Research, The Alfred Hospital, and international partners such as Leiden University Medical Centre. Awards include the NHMRC Peter Doherty Training Fellowship (2007) and Best Oral Presentation Awards (2001, 2002). She leads projects funded by NHMRC and Monash University, focusing on alloreactive T cell targets and immunopeptidome studies. Her lab actively collaborates in drug hypersensitivity research and immunotherapy development. Lab members include PhD students and alumni contributing to projects on T cell cross-reactivity and immunotherapy targets. The Mifsud Lab is part of the Immunity Program at Monash BDI, emphasizing translational research for clinical outcomes.

• Transplantation Immunology
• T Cell Cross-Reactivity
• Viral Immunity
• +3 more